TCM
FATE icon

Tufton Capital Management’s Fate Therapeutics FATE Stock Holding History

Tufton Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,858
Closed -$40K – 99
2015
Q4 		$40K Sell
11,858
-65,225
-85% -$274K 0.01% 96
2015
Q3 		$411K Buy
+77,083
New +$527K 0.09% 86

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Tufton Capital Management's FATE Position: Q1 2016 in Review

Tufton Capital Management sold out of Fate Therapeutics (FATE) in Q1 2016, closing a stake of 11,858 shares — an estimated $40K sold.

Tufton Capital Management first reported a position in FATE in Q3 2015 and held it in 2 quarters. The position peaked at $411K in Q3 2015. 46 funds tracked by Wall St. Rank hold FATE as of Q1 2016.

  • Tufton Capital Management reported no remaining Fate Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Tufton Capital Management sold 11,858 Fate Therapeutics shares in Q1 2016, an estimated $40K.
  • Tufton Capital Management first reported a position in Fate Therapeutics in Q3 2015 and held it in 2 quarters.
  • Tufton Capital Management's Fate Therapeutics position peaked at $411K in Q3 2015.
  • 46 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2016.

Based on Tufton Capital Management's 13F filing for Q1 2016, filed 13 Apr 2016.